[{"orgOrder":0,"company":"isoSolutions","sponsor":"Q BioMed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Agreement","leadProduct":"Strontium-89 Chloride","moa":"Beta-radiation","graph1":"Neurology","graph2":"Approved FDF","graph3":"isoSolutions","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"isoSolutions \/ isoSolutions","highestDevelopmentStatusID":"15","companyTruncated":"isoSolutions \/ isoSolutions"}]

Find Clinical Drug Pipeline Developments & Deals by isoSolutions

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.

                          Product Name : Metastron

                          Product Type : Radiolabeled Compounds

                          Upfront Cash : Undisclosed

                          October 08, 2021

                          Lead Product(s) : Strontium-89 Chloride

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Recipient : Q BioMed

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank